Loading clinical trials...

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity

NCT05996848•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female
•Age above or equal to 18 years at the time of signing informed consent
•1. Body Mass Index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or
•2. BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to, type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
•For participants with Type 2 diabetes (T2D) at screening the following criteria also apply:
•Diagnosed with type 2 diabetes mellitus greater than equal to 180 days before screening
•Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), thiazolidinediones, or sulphonylureas (SUs) as a single agent or in combination) according to local label
•Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 60 days before screening
•Glycated Haemoglobin (HbA1c) 7 percent-10 percent (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening

Exclusion Criteria

•For participants without T2D at screening:
•HbA1c greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening
•History of type 1 or type 2 diabetes mellitus
•For participants with T2D at screening:
•Clinically significant or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness
•Renal impairment with estimated glomerular filtration rate (eGFR) lesser than 30 milli liter per min/1.73 meter square (mL/min/1.73 m\^2), as measured by the central laboratory at screening
•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Locations (37)

Chinese People's Liberation Army General Hospital-Endocrinology

Beijing, Beijing Municipality, China

Chongqing University Three Gorges Hospital

Chongqing, Chongqing Municipality, China

Fujian Medical University Union Hospital-Endocrinology

Fuzhou, Fujian, China

Huizhou Central People's Hospital-Endocrinology

Huizhou, Guangdong, China

Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology

Hengshui, Hebei, China

The Second Hospital of Hebei Medical University-Endocrinology

Shijiazhuang, Hebei, China

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Huaihe Hospital of Henan University-Endocrinology

Kaifeng, Henan, China

Huaihe Hospital of Henan University

Kaifeng, Henan, China

The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology

Luoyang, Henan, China

Key Dates

Start Date

August 15, 2023

Primary Completion Date

January 6, 2025

Completion Date

February 22, 2025

Last Updated

January 9, 2026

Enrollment

300

ACTUAL participants

Conditions

Obesity or Overweight

Interventions

Cagrilintide

DRUG

Semaglutide

DRUG

Placebo Semaglutide

DRUG

Placebo Cagrilintide

DRUG

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

NCT07255209

Adolescents With Obesity or Overweight With Weight-Related Comorbidities

View study

RECRUITINGPHASE1

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

NCT07128888

Obesity or Overweight

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Inclusion Criteria

Exclusion Criteria

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions